17th week of 2012 patent applcation highlights part 36 |
Patent application number | Title | Published |
20120100115 | REGIONALISED ENDODERM CELLS AND USES THEREOF - The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cells markers and the like and their potential uses in a variety of applications. | 2012-04-26 |
20120100116 | NEURON GENERATION, REGENERATION AND PROTECTION - The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress. | 2012-04-26 |
20120100117 | METHOD FOR CHONDROGENIC DIFFERENTIATION OF PLURIPOTENT OR MULTIPOTENT STEM CELLS USING WNT6 - The present invention relates to methods for obtaining chondrocytes by culturing pluripotent or multipotent stem cells with a culture medium comprising Wnt6 or a derivative thereof. The inventive methods have the advantage of specifically leading to chondrogenic lineage and providing chondrocytes without differentiation towards hypertrophic chondrocytes, adipocytes or osteoblasts. | 2012-04-26 |
20120100118 | METHODS OF TREATING PIGS WITH BACILLUS STRAINS - Disclosed are methods of administering at least two | 2012-04-26 |
20120100119 | HYDROLYSIS RESISTANT ORGANOMODIFIED TRISILOXANE SURFACTANTS - Three types of trisiloxane surfactants having the basic formula: | 2012-04-26 |
20120100120 | PERFORMANCE ENHANCING COMPOSITION AND METHOD OF DELIVERING NUTRIENTS - An aqueous composition specifically adapted for supporting physical performance. The liquid composition comprises ribose, a saccharide such as glucose or dextrose, coenzyme Q10, ATP, caffeine, and D-pinitol in conjunction with minerals and electrolytes. The orally-consumed liquid composition may be sold in solid form, such as a powder, granulate, or tablet to be added to water or other fluid, or it may be sold as a shelf-stable ready-to-drink liquid. The liquid composition physiologically enhances essential energy stores and provides a supply of ingredients which support physiological generation and regeneration of ATP. | 2012-04-26 |
20120100121 | Pegylated L-Asparaginase - Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from | 2012-04-26 |
20120100122 | COMBINATION THERAPY - A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders. | 2012-04-26 |
20120100123 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ | 2012-04-26 |
20120100124 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER - The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | 2012-04-26 |
20120100125 | LOCAL DEHYDRATION FOR CARPAL TUNNEL SYNDROME - A procedure for treating carpal tunnel syndrome can involve delivering a dehydrating agent into and/or near the carpal tunnel. The dehydrating agent can reduce swelling of the flexor tendons and/or the carpal ligament in the region, thereby reducing pressure on the median nerve that also runs through the carpal tunnel. Through the use of a dehydrating agent that affects proteoglycans without affecting collagen, localized dehydration can be induced without weakening the flexor tendons, carpal ligament, and any other structures in the carpal tunnel region. | 2012-04-26 |
20120100126 | Method to Increase the Growth Velocity of Human Infants - The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds. In another aspect, the present invention relates to methods to: (X) protect the small bowel mucosa of a human infant from damage; to (Y) protect an immature intestinal epithelium of a human infant from the deleterious effects of incompletely digested and/or excess fat and/or lipid; and/or to (Z) limit accumulation of incompletely digested and/or excess fat and/or lipid in the ileum of a human infant; said methods in each case comprising the step of enteral administration of rhBSSL. | 2012-04-26 |
20120100127 | Method to Increase the Absorption of Unsaturated Fatty Acids by Human Infants - The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant. | 2012-04-26 |
20120100128 | METHODS OF AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF MAMMALIAN CELLS - A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity. | 2012-04-26 |
20120100129 | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders - A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated Aβ. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual binds one or more truncated AO protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length Aβ monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated Aβ monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (Aβ) protofibrils/oligomers and N-terminal truncated Aβ monomers employ the antibody. | 2012-04-26 |
20120100130 | Novel Receptor Hetero-Dimers/-Oligomers - A hetero-dimeric or hetero-oligomeric receptor, comprising at least one chemokine receptor subunit associated with at least one angiotensin receptor subunit. | 2012-04-26 |
20120100131 | METHOD FOR TREATMENT OF BLOOD TUMOR USING ANTI-TIM-3 ANTIBODY - Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3. The diseases for which the therapeutic use is to be examined include blood diseases in which the expression of TIM-3 is observed in bone marrow or peripheral blood, particularly blood tumor. | 2012-04-26 |
20120100132 | HUMANIZED ANTI-HUMAN TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY AND SEQUENCE THEREOF - An amino acid sequence of a humanized monoclonal antibody includes an amino acid sequence of a light chain variable region, which includes SEQ ID. NO.: 1; and an amino acid sequence of a heavy chain variable region, which comprises SEQ ID. NO.: 2, wherein SEQ ID. NO.: 1 and SEQ ID. NO.: 2 have at least one amino acid substitution which is selected from a group consisting of isoleucine at position 10 of SEQ ID. NO.: 1, being substituted with threonine, lysine at position 18 of SEQ ID. NO.: 1, being substituted with arginine, lysine at position 2 of SEQ ID. NO.: 2, being substituted with glutamine, tryptophan at position 10 of SEQ ID. NO.: 2, being substituted with leucine, lysine at position 18 of SEQ ID. NO.: 2, being substituted with arginine and glutamic acid at position 41 of SEQ ID. NO.: 2, being substituted with glycine. | 2012-04-26 |
20120100133 | USE OF ANTI-CD20 ANTIBODY FOR TREATING PRIMARY INTRAOCULAR LYMPHOMA - An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains originate from a non-murine species, said antibody being used for treating primary intraocular lymphoma. | 2012-04-26 |
20120100134 | GENETIC VARIANTS IN ANGIOGENESIS PATHWAY ASSOCIATED WITH CLINICAL OUTCOME - The invention provides methods for determining the clinical outcomes for treatment with various treatment regimens available to cancer patients based on genotypes of the patients for genetic polymorphism markers. The invention also provides kits for making the determination. | 2012-04-26 |
20120100135 | GENETIC POLYMORPHISMS ASSOCIATED WITH CLINICAL OUTCOMES OF TOPOISOMERASE INHIBITOR THERAPY FOR CANCER - The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with topoisomerase inhibitor therapy or anti-EGFR and topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. | 2012-04-26 |
20120100136 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES - This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof. | 2012-04-26 |
20120100137 | IMMUNOGLOBULINS - The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential. | 2012-04-26 |
20120100138 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2012-04-26 |
20120100139 | CD86 Antagonist Multi-Target Binding Proteins - This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions. | 2012-04-26 |
20120100140 | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE - A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics. | 2012-04-26 |
20120100141 | DRUG FUSIONS AND CONJUGATES - The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. | 2012-04-26 |
20120100142 | MONOCLONAL ANTIBODIES TO INFLUENZA H1N1 VIRUS USES THEREOF - The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies. | 2012-04-26 |
20120100143 | IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON - outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the | 2012-04-26 |
20120100144 | Biomarker and Treatment for Cancer - A correlation between expression of JMJD6 polypeptide and breast cancer metastasis exists accordingly the present invention relates a diagnostic, prognostic and therapeutic biomarker to distinguish between early and advanced/metastatic cancer particularly breast cancer, including compounds and methods to treat the same. | 2012-04-26 |
20120100145 | METHODS FOR TREATING B-CELL LYMPHOMA BY ADMINISTERING AN ANTI-CD20 ANTIBODY - The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma. | 2012-04-26 |
20120100146 | NUCLEOTIDE AND AMINO ACID SEQUENCES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases. | 2012-04-26 |
20120100147 | NOVEL ANTIBODIES AND THEIR USES IN THERAPEUTIC AND DIAGNOSTIC METHODS - Polyclonal and monoclonal antibodies which specifically recognize the KTPAF50 protein, and compositions comprising thereof are provided. Also provided are uses of the KTPAF50-specific antibodies, in the diagnosis and therapeutic of conditions such as cancer, autoimmune diseases, graft rejection, neurodegenerative diseases and diabetes. | 2012-04-26 |
20120100148 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 2012-04-26 |
20120100149 | Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent - An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed. | 2012-04-26 |
20120100150 | Influenza Hemagglutinin-Specific Monoclonal Antibodies for Preventing and Treating Influenza Virus Infection - Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin. | 2012-04-26 |
20120100151 | Antibodies or Fragments Thereof Directed Against a Staphylococcus Aureus Epitope of ISAA or ISAB - The invention concerns antibodies or fragments thereof that are directed against a | 2012-04-26 |
20120100152 | ANTI-HUMAN CD52 IMMUNOGLOBULINS - The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia. | 2012-04-26 |
20120100153 | STABLE AND SOLUBLE ANTIBODIES - The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2012-04-26 |
20120100154 | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. | 2012-04-26 |
20120100155 | PHARMACEUTICAL AGENT - Provided is a pharmaceutical agent for use in the treatment of inflammation, in a subject prone to and/or experiencing an excessive inflammatory response as a result of infection with an infectious agent and/or exposure to an allergen and/or exposure to an environmental trigger, which pharmaceutical agent comprises an agent for preventing, hindering, modulating or reducing: (a) the production, activity and/or effect of one or more cytokines; and/or (b) the functionality of one or more cells that are targets for the cytokines; and/or (c) a pathological effect caused by cells producing and/or activated by the cytokines. | 2012-04-26 |
20120100156 | Therapeutic Agent - Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions. | 2012-04-26 |
20120100157 | Biomarker and Method for Predicting Sensitivity to MET Inhibitors - Methods for determining the responsiveness of a Met-related cancer in a subject to treatment with a Met inhibitor. Kits for performing the disclosed methods are also provided. The present invention also provides a method of treating glioblastomamultiforme (GBM) in a subject in need thereof, the method comprises administering a therapeutically effective dose of a Met inhibitor in combination with a therapeutically effective dose of a epithelial growth factor receptor (EGFR) inhibitor. | 2012-04-26 |
20120100158 | ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME - A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same. | 2012-04-26 |
20120100159 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES - Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided. | 2012-04-26 |
20120100160 | Methods for Inducing Mixed Chimerism - Fusion protein-siRNA complexes that specifically target activated T cells, and methods of use thereof, are described. | 2012-04-26 |
20120100161 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer. | 2012-04-26 |
20120100162 | Cyclophosphamide in Combination with Immune Therapeutics - The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens. | 2012-04-26 |
20120100163 | SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN - The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided. | 2012-04-26 |
20120100164 | SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL - The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen. | 2012-04-26 |
20120100165 | DRUG TRANSPORTER, AND ADJUVANT AND VACCINE EACH UTILIZING SAME - An objective of the invention is to provide a drug delivery vehicle capable of allowing a vaccine or adjuvant to reach a target cell or tissue efficiently while being capable of improving the immunogenicity of the vaccine or capable of enhancing the immunostimulating effect of the adjuvant as well as a vaccine or adjuvant utilizing the same. Said drug delivery vehicle contains a multimeric protein having a coiled coil structure and a ligand molecule to a receptor of an immune cell. | 2012-04-26 |
20120100166 | Ang-2 Binding Complexes and Uses Thereof - Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described. | 2012-04-26 |
20120100167 | ALLERGEN PEPTIDE FRAGMENTS AND USE THEREOF FOR TREATMENT OF DUST MITE ALLERGIES - The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen. | 2012-04-26 |
20120100168 | CYCLOVIRUS AND METHODS OF USE - Provided herein are sequences of the genomes and encoded proteins of a novel virus, termed cyclovirus, and variants thereof. Also provided are methods of detecting cyclovirus and diagnosing cyclovirus infection, methods of treating or preventing cyclovirus infection, and methods for identifying anti-cyclovirus compounds. Further provided are vaccines and methods of preventing cyclovirus-related diseases in animals, such as pigs. | 2012-04-26 |
20120100169 | Vaccine for Cervical Cancer - The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer. | 2012-04-26 |
20120100170 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS C - The present invention provides compositions and methods for delivery of one or more hepatitis C virus (HCV) antigens using a bacterium recombinantly encoding and expressing such antigens. In certain embodiments, the bacterial platform comprises the use of attenuated and killed but metabolically active forms of | 2012-04-26 |
20120100171 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS - This invention relates to immunogenic compositions for inducing an immune response against an antigen of interest. In particular, the invention provides immunogenic compositions comprising an antigen-carrier conjugate, wherein the carrier is a bacterial toxin that contains a signal peptide. The invention also provides methods of generating immunogenic compositions with enhanced immunogenicity, comprising adding a signal peptide to the bacterial carrier in an antigen-carrier conjugate, such as a hapten-carrier conjugate. The invention also provides methods for inducing an immune response to a hapten in a subject using these immunogenic compositions. | 2012-04-26 |
20120100172 | IMMUNOGENIC STREPTOCOCCUS PNEUMONIAE PEPTIDES AND PEPTIDE-MULTIMERS - The present invention relates to immunogenic peptides, including variants and analogs derived from | 2012-04-26 |
20120100173 | METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES - The present invention relates to methods for preparing and using multichaperone-antigen complexes. The present invention uses HOP affinity molecules in affinity methods to isolate multichaperone (multi-HSP)-antigen complexes. Such complexes have use in therapy. | 2012-04-26 |
20120100174 | COMPOSITION COMPRISING SORTASE ANCHORED SURFACE PROTEINS OF STREPTOCOCCUS UBERIS - The present invention provides an immunogenic composition comprising one or more | 2012-04-26 |
20120100175 | ANTROCIN CONTAINING PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CANCER CELLS - This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer cells, lung cancer cells or breast cancer cells. | 2012-04-26 |
20120100176 | DIFFERENT SEROTYPES OF VESICULAR STOMATITIS VIRUS AS EXPRESSION VECTORS FOR IMMUNIZATION REGIMENS - Immunization platforms, immunization regimes and medicaments useful for inducing an immune response in a mammal and preventing or treating a pathogenic infection in a mammal, wherein said immunization platforms and medicaments comprise a recombinant vesicular stomatitis virus (VSV) of one serotype and a rVSV of another serotype and are used in a prime-boost immunization regime. In aspects of the invention one VSV serotype is Indiana and the other VSV serotype is New Jersey. | 2012-04-26 |
20120100177 | SALMONELLA ENTERICA PRESENTING C. JEJUNI N-GLYCAN OR DERIVATIVES THEREOF - The present invention relates to | 2012-04-26 |
20120100178 | Compositions And Methods For Treatment Of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2012-04-26 |
20120100179 | USE OF MICRORNAS TO CONTROL VIRUS HELPER NUCLEIC ACIDS - Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided. | 2012-04-26 |
20120100180 | METHODS FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLS - Methods for expansion of antigen-specific T cells are provided. Said methods include following steps: generating antigen-specific T cells by stimulation of T cells with antigen A; introducing genes encoding immune recognition molecule specific to major histocompatibility complex (MHC) molecule bound with a peptide derived from antigen B into the antigen A specific T cell to produce bi-specific T cells recognizing both target cells expressing antigen A peptide associated MHC and target cells expressing antigen B peptide associated MHC; stimulating the bi-specific T cells by antigen A for expansion of the bi-specific T cells in vitro or in vivo. Methods of the present invention can be applied to expand various of T cells with specific to cancer cells with tumor antigen peptide loaded MHC molecules for adoptive therapy against unmet medical need such as tumors etc. | 2012-04-26 |
20120100181 | Attenuation of Encephalitogenic Alphavirus and Uses Thereof - The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, C | 2012-04-26 |
20120100182 | Continuous Cell Programming Devices - The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer. | 2012-04-26 |
20120100183 | Topical base and active agent-containing compositions, and methods for improving and treating skin - The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes. | 2012-04-26 |
20120100184 | SYNTHESIS OF 1-AMINO-1,3,3,5,5,-CYCLOHEXANE MESYLATE - Process for manufacturing 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate comprising step (i):
| 2012-04-26 |
20120100185 | REGENERATION OF TISSUE WITHOUT CELL TRANSPLANTATION - The present invention provides methods and compositions for tissue regeneration without cell transplantation. | 2012-04-26 |
20120100186 | NANOPARTICULATE-BASED CONTRACEPTIVE/ANTI-HIV COMPOSITION AND METHODS - Nanoparticulate compositions which employ membrane-integrating peptides to effect contraception and/or protection against infection by sexually transmitted virus are described. | 2012-04-26 |
20120100187 | COATINGS AND METHODS FOR CONTROLLED ELUTION OF HYDROPHILIC ACTIVE AGENTS - Embodiments of the invention include multi-layer coatings and methods for controlling the elution of hydrophilic active agents. In an embodiment, the invention includes a medical device including a substrate, a primer polymer layer disposed on the substrate, an expandable layer disposed on the primer polymer layer, and a hydrophilic active agent dispersed within the expandable layer. In an embodiment, the invention includes a method of forming a medical device including depositing a primer layer onto a substrate, the primer layer comprising a primer polymer. The method can further include depositing an expandable layer onto the primer layer, the expandable layer including an expandable polymer, and a hydrophilic active agent. The expandable layer can be deposited with a solvent that is effective to solvate both the expandable polymer and the primer polymer. Other embodiments are also included herein. | 2012-04-26 |
20120100188 | SOLID STATE FORMS OF PALIPERIDONE SALTS AND PROCESS FOR THE PREPARATION THEREOF - Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I): More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid selected from the group consisting of L-(+)-tartaric acid, p-toluenesulfonic acid, maleic acid, oxalic acid, fumaric acid, acetic acid and malic acid. Provided also herein is a process for preparing substantially pure paliperidone free base using the solid state forms of paliperidone salts. | 2012-04-26 |
20120100189 | DELAYED RELEASE RASAGILINE MALATE FORMULATION - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 2012-04-26 |
20120100190 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 2012-04-26 |
20120100191 | METHODS AND DEVICES FOR DELIVERY OF PHARMACEUTICAL AGENTS WITHIN ORIFICES OF THE BODY - A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active pharmaceutical ingredient as a result of elastic stressing. | 2012-04-26 |
20120100192 | LOCAL THERAPEUTIC RELEASE DEVICE - An oral delivery device for the treatment of periodontal disease, the device being in a solid unit dosage form configured for insertion into a periodontal pocket of a patient. The device consists of: (a) a biodegradable pharmaceutically acceptable water-insoluble polymer in the form of a matrix; (b) a therapeutically effective amount of at least one anti-inflammatory agent dispersed within the matrix; (c) optionally a plasticizing agent; (d) optionally at least one of a wetting agent, a suspending agent and a dispersing agent; and (e) optionally an enzymatically biodegradable pharmaceutically acceptable water soluble polymer dispersed within the matrix. The biodegradable water-insoluble polymer is degradable by enzymatic degradation, physical disintegration or a combination thereof. Also disclosed is a periodontal implant comprising the device and a method for the treatment of periodontal disease comprising administering to a periodontal pocket of a patient in need of such treatment the delivery device. | 2012-04-26 |
20120100193 | ORAL COMPOSITIONS AND USES THEREOF - The present invention is directed to oral compositions comprising an orally-acceptable carrier and a silica abrasive comprising a precipitated amorphous silica compound having an average particle size of from 5 μm to 20 μm, oil absorption of from 60 cc/100 g to 120 cc/100 g, and an Einlehner hardness of from 4 to 11, and methods of use thereof | 2012-04-26 |
20120100194 | CHEWING GUM COMPOSITION, CHEWING GUM PRODUCT, AND METHOD FOR MANUFACTURING SAME - The invention relates to a chewing gum composition, a chewing gum product, and a method for manufacturing the same where the chewing gum composition includes: a gum base; and a gingivitis-inhibiting amount of hyaluronic acid or a physiologically acceptable salt thereof. | 2012-04-26 |
20120100195 | DEODORANT OR ANTIPERSPIRANT IMPREGNATED WIPES - An apparatus for facilitating the application of anti-perspirant and/or deodorant to an individual is disclosed. The apparatus comprises a planar element, which may be circular in shape and composed of an absorbent material, a first pocket disposed on a first side of the planar element, wherein the first pocket accommodates the individual's finger, and a deodorant and/or antiperspirant disposed on a second side of the planar element. The apparatus may further include a second pocket disposed on the first side of the planar element adjacent to the first pocket, wherein the second pocket comprises a finger-tip shape, and a wing comprised of a planar element that extends from the first side of the planar element, wherein the wing is connected to the planar element at a location between the first and second pockets. The apparatus may further include an emollient disposed on the second side of the planar element. | 2012-04-26 |
20120100196 | OILY DISPERSION AND COSMETIC MATERIAL INCORPORATING THIS OILY DISPERSION - An oily dispersion of an inorganic microparticle oxide powder that exhibits excellent texture has superior compatibility with other cosmetic material components. The oily dispersion contains only two components of a dispersion medium and a surface-treated inorganic microparticle oxide powder, wherein the dispersion medium is an oil, the surface-treated inorganic microparticle oxide powder is a powder surface-treated with branched fatty acid containing isostearic acid as a primary constituent component or a metal salt containing isostearic acid as a primary constituent component at an amount of 1 to 30% by weight with respect to the powder as a base material, and the surface-treated inorganic microparticle oxide powder has a solid concentration of 25% by weight or more and a viscosity of 2,000 mPa·s or less at 25° C. in the preparation of the oily dispersion. | 2012-04-26 |
20120100197 | NOVEL ESTERS, AND USE THEREOF - The invention relates to esters of general formula (I) R | 2012-04-26 |
20120100198 | INSECT REPELLENT TEXTILE MATERIALS - An insect repellent textile material comprises a textile substrate and at least one insect repellent compound disposed on at least one surface of the textile substrate. An insect repellent garment comprises a treated textile material as described above. A process for treating a textile material or garment comprises the steps of providing a textile material or garment, providing a liquid treatment composition, applying the liquid treatment composition to the textile material or garment, and drying the textile material or garment. | 2012-04-26 |
20120100199 | METHOD FOR TREATING A PERIODONTAL DISEASE - Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, including a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent. | 2012-04-26 |
20120100200 | System And Method For Satellite Drug Delivery - The present disclosure is directed to an implantable repository including a housing comprising at least one bioactive agent and at least one attachment member coupled to the housing, the at least one attachment member configured to couple the implantable repository to at least one of a medical device and a tissue surface. | 2012-04-26 |
20120100201 | Thermally Stable, High Tensile Strength Encapsulated Actives - In some embodiments there is a composition including a thermally stabilized active composition and a high molecular weight polymer. The thermally stabilized active composition is resistance to degradation at higher temperatures such as those used for conducting extrusion with high molecular weight polyvinyl acetate. | 2012-04-26 |
20120100202 | MANUFACTURING OF SMALL FILM STRIPS - The present invention relates to methods for forming films. In particular, the present invention relates to the formation of films on a substrate via the use of individual pumps to deposit individual wet film products onto a substrate. | 2012-04-26 |
20120100203 | Fabrication of Biscrolled Fiber Using Carbon Nanotube Sheet - Fabrication of yarns or other shaped articles from materials in powder form (or nanoparticles or nanofibers) using carbon nanotube/nanofiber sheet as a platform (template). This includes methods for fabricating biscrolled yarns using carbon nanotube/nanofiber sheets and biscrolled fibers fabricated thereby. | 2012-04-26 |
20120100204 | TGF-Beta Stimulating Agent Compositions and Combinations - Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided. | 2012-04-26 |
20120100205 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES - The invention suggests amphoteric lipids wherein one or more amphoteric groups having an isoelectric point between 4 and 9 are substituted on a membranous or membrane-forming amphiphilic substance, as well as liposomes containing such compounds. | 2012-04-26 |
20120100206 | TARGETED LIPOSOMES COMPRISING N-CONTAINING BISPHOSPHONATES AND USES THEREOF - The present is based on the finding that folate targeted liposomal alendronate (FT-AL-L) was significantly more potent against two tested cancer cell lines than the free alendronate (AL) or the non-targeted liposomal alendronate (AL-L), as observed by the increased cytotoxicity of the folate targeted liposomal alendronate. Thus, the present disclosure provides targeted liposomes comprising a membrane and an intraliposomal core, the membrane comprising at least one liposome forming lipid and a targeting moiety, such as folate, exposed at the membrane's outer surface; and the intraliposomal core comprising encapsulated therein least one N-containing bisphosphonate. Also provided by the present disclosure are methods of use of the targeted liposomes such as for the treatment of a disease or disorder. | 2012-04-26 |
20120100207 | PROCESS FOR PRODUCING LIPOSOMES BY TWO-STEP EMULSIFICATION METHOD UTILIZING OUTER AQUEOUS PHASE CONTAINING SPECIFIC DISPERSING AGENT, PROCESS FOR PRODUCING LIPOSOME DISPERSION OR DRY POWDER THEREOF USING THE PROCESS FOR PRODUCING LIPOSOMES, AND LIPOSOME DISPERSION OR DRY POWDER THEREOF PRODUCED THEREBY - [Problem] To provide a process for producing liposomes, a liposome dispersion or a dry powder of the dispersion by a two-step emulsification method using an additive (dispersing agent) by which a liposome dispersion and a dry powder thereof which can inhibit leakage of an encapsulated drug or the like from liposomes even in the long-term storage and can be stably used over a long period of time are obtained. [Solution to problem] A process for producing liposomes by a two-step emulsification method characterized by using, in the secondary emulsification step, an outer aqueous phase containing a dispersing agent which forms no molecular self-aggregate or a dispersing agent which exclusively forms molecular self-aggregates having a volume mean particle diameter of not more than 10 nm (said dispersing agent being referred to as a “specific dispersing agent” hereinafter), and a process for producing a liposome dispersion or a dry powder thereof utilizing the process for producing liposomes. The specific dispersing agent preferably contains at least one of gelatin, albumin, dextran and a polyalkylene oxide-based compound. | 2012-04-26 |
20120100208 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2012-04-26 |
20120100209 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE - The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile. | 2012-04-26 |
20120100210 | COMPOSITION FOR THE ADMINISTRATION OF POLYMERIC DRUGS - Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance. | 2012-04-26 |
20120100211 | MATERIAL AND PROCESS FOR INCORPORATION OF LOW DOSAGE ACTIVE PHARMACEUTICAL INGREDIENTS AND USE THEREOF - A low dose API pharmaceutical tablet having excellent content uniformity is provided. The tablet is formed by spray coating a support excipient with the API. The resulting composition is suitable for direct compression tablet formulation without the need for an additional granulation step to uniformly coat the API onto the support excipient. The support excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the support excipient components. | 2012-04-26 |
20120100212 | TABLET HAVING HOLLOW STRUCTURE - A water floatable tablet, which is either:
| 2012-04-26 |
20120100213 | PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE - Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease. | 2012-04-26 |
20120100214 | Sustained-Release Tablet and Process for Preparing the Same - A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described. | 2012-04-26 |